Prevention of Clostridioides difficile Infection with Probiotics

Rationale for Probiotic Use with Antibiotics

Prophylactic probiotics may be considered for patients receiving Omnicef (cefdinir) to reduce the risk of Clostridioides difficile infection, particularly in high-risk settings or during outbreaks 1, 2
Certain probiotics have shown efficacy in preventing C. difficile infection when administered concurrently with antibiotics 2, 3
The efficacy of probiotics is both strain-specific and disease-specific, meaning not all probiotics are equally effective 1

Recommended Probiotic Strains

The American Gastroenterological Association (AGA) conditionally recommends the use of probiotics with antibiotics, citing low quality of evidence, and suggests the use of specific strains such as Saccharomyces boulardii 2, 3
A two-strain combination of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R may be beneficial 3, 4
A three-strain combination of L. acidophilus, L. delbrueckii subsp bulgaricus, and Bifidobacterium bifidum may also be effective 3, 4
A four-strain combination of L. acidophilus, L. delbrueckii subsp bulgaricus, B. bifidum, and Streptococcus salivarius subsp thermophilus may be considered 3, 4

Important Considerations and Cautions

Probiotics are contraindicated in immunocompromised patients due to the risk of bacteremia or fungemia 1, 5
The Infectious Diseases Society of America (IDSA) states there are insufficient data to recommend probiotics for primary prevention of C. difficile infection outside of clinical trials 6, 7
Probiotics should be administered during the course of antibiotic therapy and can be continued for the duration of antibiotic treatment 1

Clinical Decision Algorithm

High-risk patients, such as the elderly, those with prolonged hospitalization, severe underlying illness, or previous C. difficile infection, may benefit from probiotic supplementation 1, 3, 7
Probiotics should be started at the beginning of antibiotic therapy and continued for the duration of treatment, with consideration of continuing for 1-2 weeks after antibiotics are completed 1, 6

Evidence Quality and Limitations

The overall quality of evidence supporting probiotic use with antibiotics is rated as low 2, 3
Many studies on probiotics have methodological limitations, including heterogeneity in populations, probiotic strains, and outcome measures 1, 2
Publication bias may exist, as many registered trials on this topic were not linked to subsequent publications 2

Prevention of Antibiotic-Associated Diarrhea with Probiotics

Evidence-Based Probiotic Options

The American Gastroenterological Association recommends Saccharomyces boulardii as the most effective single-strain probiotic with clindamycin, showing a 59% reduction in C. difficile-associated diarrhea recurrence compared to placebo 8, 9
A two-strain combination of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R reduces the risk of C. difficile-associated diarrhea by 78% compared to placebo 10
A three-strain combination of L. acidophilus, L. delbrueckii subsp bulgaricus, and Bifidobacterium bifidum reduces the risk by 65% 10
A four-strain combination of L. acidophilus, L. delbrueckii subsp bulgaricus, B. bifidum, and Streptococcus salivarius subsp thermophilus reduces the risk by 72% 10

Administration Guidelines

The World Journal of Emergency Surgery recommends continuing probiotic therapy throughout the entire course of antibiotic treatment 11

Important Considerations

The World Journal of Emergency Surgery states that probiotics should not be used in immunocompromised patients due to risk of bacteremia or fungemia 11

Clinical Decision Algorithm

For immunocompetent patients, the American Gastroenterological Association recommends starting with Saccharomyces boulardii (recommended dose: 1g or 3×10¹⁰ CFU/day) 8, 9
For patients with a history of C. difficile infection, a multi-strain combination approach with either the three-strain or four-strain formulation may be considered 10, 11

Evidence Limitations

The overall quality of evidence supporting probiotic use with antibiotics is rated as low to moderate 8, 10

Probiotics for Prevention of Clostridioides difficile Infection

Recommended Probiotic Strains for C. difficile Prevention

The American Gastroenterological Association (AGA) conditionally recommends Saccharomyces boulardii for prevention of C. difficile infection in patients receiving antibiotics, which reduces risk by 59% (RR, 0.41; 95% CI, 0.22-0.79) 12, 13
The AGA also recommends a two-strain combination of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R, which reduces risk by 78% (RR, 0.22; 95% CI, 0.11-0.42) 12

Evidence Quality and Limitations

The overall quality of evidence supporting probiotic use for C. difficile prevention is rated as low 12, 13
A Cochrane review of 39 studies with 9,955 patients found probiotics reduced overall risk of C. difficile infection vs placebo (RR, 0.40; 95% CI, 0.30-0.52) 12, 14
The beneficial effect was primarily observed in high-risk populations (>15% baseline risk), with no significant effects in low-risk patients 12, 13

Important Cautions and Contraindications

Patients with severe illness may be at higher risk of adverse events 12, 15
The benefit-risk profile may not favor probiotic use in outpatient settings with low C. difficile risk 12, 14

Gaps in Current Evidence

Limited data on probiotics for treatment of established C. difficile infection 13, 16
Inconsistent reporting of potential harms across studies 15, 16

Probiotic Use with Antibiotics: Safety and Efficacy

Introduction to Probiotic Use

The European Paediatric Association warns against probiotic use in high-risk populations, including immunocompromised patients, critically ill patients, those with central venous catheters, cardiac valvular disease, and premature neonates, due to documented cases of probiotic-related sepsis 17

Special Populations and Probiotic Recommendations

For pediatric populations, Lactobacillus rhamnosus GG (LGG) and Saccharomyces boulardii are specifically recommended for prevention of antibiotic-associated diarrhea 17
The American Gastroenterological Association provides conditional recommendations based on low-to-moderate quality evidence for probiotic use in high-risk settings, with a substantial clinical benefit 18

Probiotic Administration and Safety

The American Gastroenterological Association recommends taking probiotics at the beginning of antibiotic therapy and continuing throughout the entire antibiotic course, with a dosing of at least 10⁹ CFU/day for most Lactobacillus strains 17

Evidence Quality and Clinical Context

A Cochrane review of 39 studies with 9,955 patients demonstrated that probiotics reduce C. difficile infection risk by 60% (RR 0.40, 95% CI 0.30-0.52), with the benefit most pronounced in high-risk populations (>15% baseline risk of C. difficile) 18
The Infectious Diseases Society of America states there are insufficient data to recommend probiotics for primary C. difficile prevention outside clinical trials, but the American Gastroenterological Association and multiple Cochrane reviews support conditional use with specific strains in high-risk populations 18
Given the low risk of adverse events in immunocompetent patients and substantial potential benefit (64% reduction in antibiotic-associated diarrhea), the evidence favors probiotic use in appropriate populations 18
The American Gastroenterological Association and the European Paediatric Association recommend against probiotic use in immunocompromised patients due to the risk of bacteremia or fungemia 17

Probiotic Use for Prevention of Antibiotic‑Associated Diarrhea

Recommended Strain, Dose, and Timing

In otherwise healthy adults, the American Gastroenterological Association (AGA) conditionally recommends Saccharomyces boulardii at 1 g (≈3 × 10¹⁰ CFU) daily, initiated at the start of antibiotic therapy and continued for the entire duration of the antibiotic course. 19

Rationale for a Yeast‑Based Probiotic

Antibiotics do not kill yeast, so S. boulardii remains viable when administered concurrently with antibiotics, ensuring continuous probiotic exposure throughout treatment. 19
Across multiple randomized trials, S. boulardii was the only single‑strain probiotic that showed a significant reduction in Clostridioides difficile‑associated diarrhea, confirming its unique efficacy among single‑strain products. 20

Evidence Quality and Guideline Position

The AGA Technical Review rates the overall quality of evidence supporting probiotic use for antibiotic‑associated diarrhea as low, citing heterogeneity in study populations, probiotic strains, and outcome definitions. Nevertheless, the association is considered clinically meaningful, leading to a conditional recommendation for S. boulardii. 20

Clinical Caveats

Strain specificity matters: efficacy is highly dependent on the probiotic strain; not all probiotics are interchangeable. This underscores the need to select S. boulardii (or other evidence‑based strains) rather than generic formulations. 20
Probiotics should not be used as monotherapy for established C. difficile infection; limited data exist to support such use, and current guidance advises against it. 21

Probiotic Use During Antibiotic Therapy – Evidence‑Based Guidance

1. Overall Efficacy of Concurrent Probiotic Administration

Randomized clinical trials demonstrate that giving probiotic preparations at the same time as antibiotics provides a clinically meaningful benefit, indicating that enough viable organisms survive to colonize the gut. Evidence level: low‑to‑moderate quality. [22][23]

2. Strain‑Specific Efficacy

2.1. Bacterial‑Based Probiotics

A two‑strain combination of Lactobacillus acidophilus CL1285 + Lactobacillus casei LBC80R reduces the risk of Clostridioides difficile‑associated diarrhea by 78 % (relative risk 0.22; 95 % CI 0.11‑0.42) when administered with antibiotics. Evidence level: low‑to‑moderate. 23
Multi‑strain formulations containing three to four bacterial species (e.g., L. acidophilus, L. delbrueckii, and Bifidobacterium spp.) achieve a 65‑72 % reduction in C. difficile‑associated diarrhea risk. Evidence level: low‑to‑moderate. 23

2.2. Yeast‑Based Probiotic

Saccharomyces boulardii given at 1 g daily (≈3 × 10¹⁰ CFU) lowers the incidence of C. difficile‑associated diarrhea by 59 % (relative risk 0.41; 95 % CI 0.22‑0.79). Because antibiotics do not affect yeast, timing separation from antibiotic doses is not required. Evidence level: low‑to‑moderate. 23

3. Quality of the Supporting Evidence

The collective body of evidence for probiotic use alongside antibiotics is rated low to moderate owing to heterogeneity in study populations, probiotic strains, dosing regimens, and outcome definitions. [22][23]
Despite this limitation, the observed clinical benefit is substantial, with a 60‑78 % reduction in C. difficile infection rates depending on the probiotic strain, and adverse events are rare in immunocompetent individuals. [22][23]

4. Impact on Gut Microbiome Recovery

Recent data indicate that probiotic supplementation may alter the natural trajectory of gut microbiota restoration after a course of antibiotics, compared with no probiotic intervention. Evidence level: low‑to‑moderate. [22][23]
The long‑term clinical significance of this altered recovery pattern remains unknown, but current evidence suggests it does not outweigh the short‑term benefit of preventing C. difficile infection in high‑risk patients. [22][23]